NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Aurora Cannabis Inc. ACB
7 fiscal years on record · CAD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
CAD 343.3M
▲ 27.3% vs FY2023
EPS · FY24
CAD 0.04
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
0.3%
Net margin · FY24
0.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CAD 343.3M
Revenue, FY2024 · full 7-year series below
Revenue
Net income
0 cents of every revenue dollar became profit this year.
Per share
CAD 0.04
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
0.3%
Return on equity, FY2024
ROE
Operating margin1.4%
Net margin0.5%
Return on assets0.2%
Each CAD of equity produced 0 cents of profit this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+15.8%
+5.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CAD 852.7M
total assets, end of FY2024
Total assetsCAD 852.7M
EquityCAD 567.2M
CashCAD 137.9M
Gross debtCAD 42.5M
Net debtCAD -95.4M
Current ratio4.31×
The company holds more cash than debt.
History
7 fiscal years
Every figure from documents filed with the SEC · CAD
Metric
2024
2023
2021
2020
2019
2018
2017
Revenue CAD B
0.3
0.3
0.2
0.2
0.3
0.2
0.1
Operating income CAD B
0.0
−0.0
−0.2
−0.3
−0.5
−0.3
−0.1
EBITDA CAD B
0.0
−0.0
−0.2
−0.2
−0.4
−0.3
−0.1
Income tax CAD B
0.0
−0.0
−0.0
−0.0
−0.1
−0.0
0.0
Net income CAD B
0.0
−0.1
−1.7
−0.7
−3.3
−0.3
0.1
EPS, diluted CAD
0.04
−1.52
−7.99
−4.10
·
−0.29
0.15
Dividend / sh CAD
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
0.3
−12.4
−127.3
−33.1
−100.5
−9.9
4.6
Shares out B
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
20 of 20
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed